Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ERAS-601

PreclinicalSmall molecule

ERAS-601 is one of 24 small molecule programs targeting Chordoma. It is currently in Preclinical.

2

Indications

5

Total Trials

3

Active Trials

23

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChordomaActive, not recruiting

Advanced or Metastatic Solid TumorsActive, not recruiting

ChordomaPhase 1/Phase 2

Active, not recruiting

Advanced or Metastatic Solid TumorsPreclinical

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Chordoma

#DrugCompanyPhaseTrials

Gleevec

Ibrance

Keytruda

Opdualag

Bristol-Myers Squibb

Gilotrif

Boehringer Ingelheim

Erbitux

Bavencio

Cytoxan

BBaxter Healthcare Corporation

Opdivo

Bristol-Myers Squibb

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Advanced or Metastatic Solid Tumors

NCT04866134

Q2 2027

Phase 1/2Recruiting

Chordoma

NCT06957327

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors2 trials

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting·EErasca, Inc.·Phase 1·NCT04670679·90 enrolled

A Phase 1b/2, Open-label, Multi-center Study of ERAS-007 (ERK Inhibitor) Administered as Monotherapy or in Combination With ERAS-601 (SHP2 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1)

Active, not recruiting·EErasca, Inc.·Preclinical·NCT04866134·200 enrolled

Advanced NSCLC1 trial

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Completed·EErasca, Inc.·Phase 1·NCT04959981·24 enrolled

Chordoma1 trial

A Study of ERAS-601 in People With Chordoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT06957327·46 enrolled

Hematologic Malignancies1 trial

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Withdrawn·EErasca, Inc.·Phase 1/2·NCT05279859

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ERAS-601. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ERAS-601 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ERAS-601. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Erasca, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EErasca, Inc.

Related News